Pojamide: an HDAC3-selective ferrocene analogue with remarkably enhanced redox-triggered ferrocenium activity in cells

Cory A. Ocasio, Supojjanee Sansook, Rhiannon Jones, Justin M. Roberts, Thomas G. Scott, Nikolaos Tsoureas, Peter Coxhead, Matthew Guille, Graham J. Tizzard, Simon J. Coles, Helfrid Hochegger, James E. Bradner, John Spencer

Research output: Contribution to journalArticlepeer-review

90 Downloads (Pure)

Abstract

A ferrocene containing o-aminoanilide, N1-(2-aminophenyl)-N8-ferrocenyloctanediamide (2b, Pojamide) displayed nanomolar potency vs HDAC3. In comparison to RGFP966, a potent and selective HDAC3 inhibitor, Pojamide displayed superior activity in HCT116 colorectal cancer cell invasion assays; however, TCH106 and romidepsin, potent HDAC1 inhibitors, outperformed Pojamide in cellular proliferation and colony formation assays. Together, these data suggest that HDAC1,3 inhibition is desirable to achieve maximum anticancer benefits. Additionally, we explored Pojamide-induced redox pharmacology. Indeed, treating HCT116 cells with Pojamide, SNP (sodium nitroprusside), and glutathione (GSH) led to greatly enhanced cytotoxicity and DNA damage, attributed to activation to an Fe(III) species.
Original languageEnglish
JournalOrganometallics
Early online date21 Aug 2017
DOIs
Publication statusEarly online - 21 Aug 2017

Keywords

  • RCUK
  • EPSRC

Fingerprint

Dive into the research topics of 'Pojamide: an HDAC3-selective ferrocene analogue with remarkably enhanced redox-triggered ferrocenium activity in cells'. Together they form a unique fingerprint.

Cite this